Avalo Therapeutics (AVTX)

• Market cap: $286M
• 1 day: -3.48%
• 5 days: -11.59%
• 1 month: 14.93%
• 3 months: 79.38%
• 6 months: 220.52%
• Year to date: 90.87%
• 1 year: 18.83%
• 5 years: -99.73%
• 10 years: -99.86%
• Sector: Healthcare
• Industry: Biotechnology

About: Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 23